ICMR Reports 82% Efficacy In Phase 2 Trials For Indigenous Dengue Vaccine

The Indian Council of Medical Research (ICMR) has announced the successful completion of Phase 2 clinical trials for a new, indigenous vaccine designed to combat Dengue fever. The trials, which were conducted across 10 diverse sites in India, demonstrated an impressive efficacy rate of 82% in preventing severe cases of the disease. This development marks a significant milestone in India's public health efforts to manage the recurring seasonal outbreaks of Dengue.

The study involved a comprehensive evaluation of the vaccine's safety and immune response across various demographics. By focusing on indigenous development, the ICMR aims to create a cost-effective and accessible solution tailored to the specific strains of the virus prevalent in the Indian subcontinent. The high efficacy rate observed in the Phase 2 cohort provides a strong foundation for the next stage of clinical validation, which is essential for regulatory approval and eventual mass distribution.

With the success of Phase 2, the ICMR has scheduled Phase 3 clinical trials to commence in early 2027. This larger study will involve a more extensive cohort of participants to confirm the vaccine's long-term safety and efficacy profile. If successful, the vaccine could be a game-changer for India's healthcare system, potentially reducing the annual burden on hospitals and saving thousands of lives during peak transmission seasons. Public health officials are optimistic that this vaccine will become a cornerstone of India's infectious disease prevention strategy.